Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. (1,1'-biphenyl)-2-carboxamide, N-(4-((4,5-dihydro-2-methylimidazo(4,5-d)(1)benzazepin-6(1h)-yl)carbonyl)phenyl)-
2. (1,1'-biphenyl)-2-carboxamide, N-(4-((4,5-dihydro-2-methylimidazo(4,5-d)(1)benzazepin-6(1h)-yl)carbonyl)phenyl)-, Monohydrochloride
3. 4''-((4,5-dihydro-2-methylimidazo(4,5-d)(1)benzazepin-6(1h)-yl)carbonyl)-2-biphenylcarboxanilide
4. Ci-1025
5. Conivaptan
6. Conivaptan Hcl
7. Vaprisol
8. Ym 087
9. Ym-087
10. Ym087
1. 168626-94-6
2. Conivaptan Hcl
3. Vaprisol
4. Ym 087
5. Conivaptan (hydrochloride)
6. Ci-1025
7. Conivaptan Hydrochloride [usan]
8. Ym-087
9. N-[4-(2-methyl-4,5-dihydro-3h-imidazo[4,5-d][1]benzazepine-6-carbonyl)phenyl]-2-phenylbenzamide Hydrochloride
10. Ym087
11. Conivaptan Hcl (vaprisol)
12. 8626-94-6
13. Chebi:31430
14. 75l57r6x36
15. (1,1'-biphenyl)-2-carboxamide, N-(4-((4,5-dihydro-2-methylimidazo(4,5-d)(1)benzazepin-6(1h)-yl)carbonyl)phenyl)-, Monohydrochloride
16. [1,1'-biphenyl]-2-carboxamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1h)-yl)carbonyl]phenyl]-, Hydrochloride (1:1)
17. 4'-((4,5-dihydro-2-methylimidazo(4,5-d)(1)benzazepin-6(1h)-yl)carbonyl)-2-biphenylcarboxanilide Monohydrochloride
18. N-(4-(2-methyl-1,4,5,6-tetrahydrobenzo[b]imidazo[4,5-d]azepine-6-carbonyl)phenyl)-[1,1'-biphenyl]-2-carboxamide Hydrochloride
19. 4'-[(2-methyl-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepin-6-yl)-carbonyl]-2-phenylbenzanilide Monohydrochloride
20. N-[4-({4-methyl-3,5,9-triazatricyclo[8.4.0.0^{2,6}]tetradeca-1(14),2(6),4,10,12-pentaen-9-yl}carbonyl)phenyl]-2-phenylbenzamide Hydrochloride
21. Smr004701209
22. Unii-75l57r6x36
23. Vaprisol (tn)
24. Mls006010030
25. Mls006010233
26. Schembl387232
27. Conivaptan Hcl [vandf]
28. Chembl1201108
29. Dtxsid70168585
30. Vaprisol, Conivaptan Hydrochloride
31. Bcp28426
32. Ex-a1128
33. Conivaptan Hydrochloride (jan/usan)
34. Conivaptan Hydrochloride [mi]
35. Hy-18347a
36. Mfcd00945712
37. Conivaptan Hydrochloride [jan]
38. Akos015994583
39. Akos025401635
40. Ccg-269940
41. Cs-2015
42. Fe-0225
43. Conivaptan Hydrochloride [mart.]
44. Conivaptan Hydrochloride [who-dd]
45. Ac-23918
46. N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1h)-yl)carbonyl]phenyl]-[1,1'-biphenyl]-2-carboxamide Hydrochloride
47. Db-064699
48. Am20090724
49. Ft-0657174
50. Sw219215-1
51. Conivaptan Hydrochloride [orange Book]
52. D01236
53. 626c946
54. A810997
55. J-010472
56. Q27114306
57. 4''-((4,5-dihydro-2-methylimidazo(4,5-d)(1)benzazepin-6(1h)-yl)carbonyl)-2-biphenylcarboxanilide Monohydrochloride
58. 4'-[(2-methyl-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepin-6-yl)carbonyl]-2-phenylbenzanilide Hydrochloride
59. N-(4-(2-methyl-1,4,5,6-tetrahydrobenzo[b]imidazo[4,5-d]azepine-6-carbonyl)phenyl)-[1,1'-biphenyl]-2-carboxamidehydrochloride
60. N-[4-(2-methyl-4,5-dihydro-1h-imidazo[4,5-d][1]benzazepine-6-carbonyl)phenyl]-2-phenylbenzamide;hydrochloride
61. N-[4-(2-methyl-4,5-dihydro-3h-imidazo[4,5-d][1]benzazepine-6-carbonyl)phenyl]-2-phenylbenzamide;hydrochloride
62. N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1h)-yl)carbonyl]phenyl]-[1,1?-biphenyl]-2-carboxamide Hydrochloride
63. N-{4-[(2-methyl-4,5-dihydroimidazo[4,5-d][1]benzazepin-6(1h)-yl)carbonyl]phenyl}biphenyl-2-carboxamide Hydrochloride
| Molecular Weight | 535.0 g/mol |
|---|---|
| Molecular Formula | C32H27ClN4O2 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 4 |
| Exact Mass | 534.1822538 g/mol |
| Monoisotopic Mass | 534.1822538 g/mol |
| Topological Polar Surface Area | 78.1 Ų |
| Heavy Atom Count | 39 |
| Formal Charge | 0 |
| Complexity | 820 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 2 | |
|---|---|
| Drug Name | Vaprisol |
| PubMed Health | Conivaptan (Injection) |
| Drug Classes | Endocrine-Metabolic Agent |
| Drug Label | Conivaptan hydrochloride is chemically [1,1'-biphenyl]-2-carboxamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-, monohydrochloride, having a molecular weight of 535.04 and molecular formula C32H26N4O2HCl. Th... |
| Active Ingredient | Conivaptan hydrochloride |
| Dosage Form | Injectable |
| Route | injection |
| Strength | 20mg |
| Market Status | Prescription |
| Company | Astellas |
| 2 of 2 | |
|---|---|
| Drug Name | Vaprisol |
| PubMed Health | Conivaptan (Injection) |
| Drug Classes | Endocrine-Metabolic Agent |
| Drug Label | Conivaptan hydrochloride is chemically [1,1'-biphenyl]-2-carboxamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-, monohydrochloride, having a molecular weight of 535.04 and molecular formula C32H26N4O2HCl. Th... |
| Active Ingredient | Conivaptan hydrochloride |
| Dosage Form | Injectable |
| Route | injection |
| Strength | 20mg |
| Market Status | Prescription |
| Company | Astellas |
Antidiuretic Hormone Receptor Antagonists
Endogenous compounds and drugs that inhibit or block the activity of ANTIDUIRETIC HORMONE RECEPTORS. (See all compounds classified as Antidiuretic Hormone Receptor Antagonists.)
Related Excipient Companies
Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Fillers, Diluents & Binders
Taste Masking
Parenteral
Co-Processed Excipients
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Market Place
ABOUT THIS PAGE
A Conivaptan manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Conivaptan, including repackagers and relabelers. The FDA regulates Conivaptan manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Conivaptan API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Conivaptan manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Conivaptan supplier is an individual or a company that provides Conivaptan active pharmaceutical ingredient (API) or Conivaptan finished formulations upon request. The Conivaptan suppliers may include Conivaptan API manufacturers, exporters, distributors and traders.
click here to find a list of Conivaptan suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Conivaptan Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Conivaptan GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Conivaptan GMP manufacturer or Conivaptan GMP API supplier for your needs.
A Conivaptan CoA (Certificate of Analysis) is a formal document that attests to Conivaptan's compliance with Conivaptan specifications and serves as a tool for batch-level quality control.
Conivaptan CoA mostly includes findings from lab analyses of a specific batch. For each Conivaptan CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Conivaptan may be tested according to a variety of international standards, such as European Pharmacopoeia (Conivaptan EP), Conivaptan JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Conivaptan USP).
LOOKING FOR A SUPPLIER?
